According to the World Health Organization (WHO), cancer is the second leading cause of death in the world. In 2018 alone, 9.6 million people worldwide died of cancer, accounting for about 1/6Read More…
Monoclonal Drug Development and Market Conditions
B lymphocytes can only produce a proprietary antibody against an antigen determinant, so it has the characteristics of highly specific physical and chemical properties, single biological activity, strong binding specificity with antigenRead More…
Focus on the Technology Bottleneck of Monoclonal Antibody Drugs
The Antibodies are secreted by plasma cells transformed from B cells, and each B cell line can produce only one specific antigenic determinant. The antibody, produced from a single cell line, isRead More…
Antibodies Cure Guinea Pigs Infected with Ebola Virus, Raising Hopes for Human Treatment of Ebola
The outbreak of Ebola in 2014 in West Africa killed more than 11000 people. At the time, scientists were working on several experimental vaccines and treatments, but none of them were approvedRead More…
Based on Single Domain Antibody CAR-T Cells Are Expected to Treat Solid Tumors
Most CAR-T cell therapies require targeting cancer cell-specific antigens. Now, there is a new way to target the environment around the tumor, which comes from nanobodies naturally produced by free alpacas, camelsRead More…
Nat Commun: Melanin Nanoparticles Help Alleviate the Deterioration of Cancer
Melanin protects us from the sun’s destructive rays by absorbing light energy and converting it into heat. A recent study has shown that this can make it a very effective tool forRead More…
Nat Cell Bio: “Mirror” Synthetic Biology Technology to Improve the Therapeutic Effect of Antibody Molecules
Scientists, from the German Cancer Research Center (DKFZ), have successfully reconstructed biomolecules in the form of images. The goal of the researchers is to create a mirror artificial protein synthesis system. InRead More…
Next the Middle of a Whirlwind: Alzheimer’s Disease Diagnostic Market
Alzheimer’s disease (AD) is a neurodegenerative disease common in the elderly. The main pathological changes were diffuse atrophy of cerebral cortex, neurofibrillary tangles and the formation of a large number of senileRead More…
First CD79b Targeted Therapy! Roche Antibody Drug Conjugate Polatuzumab Vedotin is Given Priority Review by FDA in the United States
Swiss pharmaceutical giant Roche recently announced that the Food and Drug Administration (FDA) has accepted the biologics licensing application (BLA) of polatuzumab vedotin, antibody drug conjugate (ADC), and granted priority review. TheRead More…
The World’s First Nanobody Drug! Sanofi Cablivi is Approved by FDA for the Treatment of Rare Thrombotic Diseases
French pharmaceutical giant Sanofi recently announced that the US Food and Drug Administration (FDA) has approved the nanobody drug Cablivi (caplacizumab), combined with plasma exchange and immunosuppressive therapy. For the treatment ofRead More…